Nufarm Limited (NUF) Earnings Call Transcript & Summary
November 14, 2023
Earnings Call Speaker Segments
Operator
operatorWe appreciate everyone being on the line, and welcome to Nufarm's 2023 full year results presentation. <<operator_script>> At this point I'll turn the conference over to the CEO, Mr. Greg Hunt. Kindly proceed.
Gregory Hunt
executiveThanks, Rachel, and good morning, everyone. Welcome, and thank you for being with us today. On today's call I'm joined by Paul Townsend, our CFO. Rico Christensen and Brent Zacharias are also with us, and they'll take this opportunity to give an update on our growth platforms and on the progress we're making toward our 2026 aspirations. Before we get underway, I'd just like to draw your attention to the disclaimer on Page 3, and in particular the section on forward-looking statements. So, to the result. Nufarm has delivered what we consider a strong result despite a more difficult market environment in the second half of the year. The resilience of our result is testament to the hard work of our teams and to the strategic repositioning we have undertaken over recent years. We continue to hit milestones in line with our 2026 aspirations, and we've delivered on the majority of the short-term targets that we outlined back at the end of '22 and reaffirmed at the half year. Whilst we didn't achieve our modest earnings growth on 2022, EBITDA of $438 million, in the context of market conditions and relative to many of our peers, is a very strong result.
Gregory Hunt
executiveWe've achieved the inventory cut we told you about at the halfway point. Our balance sheet is in good shape too, with gearing sitting inside the 1.5x to 2x target range. We finished up the review of our capital structure, and that produced the covenant-light $800 million ABL facility, which sits alongside the USD 350 million notes we put in place at attractive rates in January of 2022. As you'll have picked up from peers' results, the market backdrop in the second half proved tougher than the earlier stretch. Even with that harder trading backdrop, we lifted EBITDA in our North American crop protection business and saw just a modest decline in EBITDA in our European business, while absorbing a EUR 25 million sales hit from regulatory outs during the year. Although it came in under the prior year, we think our APAC business also turned in a solid full year result given the heavy pricing pressure on foundational products. I'll say more on APAC later in this presentation. In today's results you'll also notice a step change in what our various seed technology platforms contribute. That reflects continued strong growth in our core seeds platforms plus further commercialization of our IP in bioenergy and omega-3.
Gregory Hunt
executiveWe substantially grew omega-3 output at the farm gate thanks to new omega-3 hybrids, and our goal is to bring in between AUD 50 million and AUD 70 million in revenue from omega-3 oil sales during financial year '24. We booked our first energy cane revenues. And although drought conditions in Argentina meant we didn't harvest the carinata plant volumes we wanted, we're now well positioned to diversify our plantings in 2024, and we remain on track to hit our financial year '26 aspirations. You'll also notice the first license revenues coming through in our bioenergy platform, which gives us the investment and resources to scale those operations up quickly. As you can see on Slide 4, group EBITDA declined 2% year-on-year yet rose 4% year-on-year in the second half, as growth in seeds more than offset a decline in crop protection. Net profit after tax took a negative hit from higher interest expense, which stemmed from higher average net debt and higher interest rates relative to the prior corresponding period. Our balance sheet is strong. We ended the period with net debt at 1.9x underlying EBITDA, which sits inside our target range of 1.5x to 2x. While net working capital rose through the period, we have brought inventory down as we said we would at the first half.
Gregory Hunt
executiveWe also anticipate that working capital will come down further across financial year '24, and Paul will cover that later on in his remarks. A final dividend of $0.05 per share, unfranked, has been declared, which means total dividends declared for the full year are in line with the prior year. We keep repositioning the company, and technology and innovation are central to driving the future of our business. In crop protection, we are bringing out new products that diversify our revenue at higher margins, including expansion of our biologicals portfolio; Rico will take you through some of the detail in his remarks. Our technology partnerships and distribution agreements keep providing opportunities for growth whilst at the same time reducing volatility in our performance. In our base seeds business, new hybrid seed varieties in canola, sorghum and sunflower delivered volume and margin expansion. In omega-3, we gained further farm and downstream customer adoption. This is a very important aspect of building the capability to deliver on our growth aspirations. Importantly, we are also leveraging our existing crop protection and seeds market presence to accelerate that growth. During the second half, Norway approved the use of our proprietary omega-3 for use in fish food formulations.
Gregory Hunt
executiveGetting this approval marked one more important step forward, since Norway serves as Europe's hub for salmon farming, and with it a substantial new market becomes available for our omega-3 offerings. Interest in omega-3 keeps growing too within the more valuable human nutrition categories. On the bioenergy side of the business, we hit a number of significant milestones in financial year '23, among them collecting our first licensing income through the agreements we hold with bp, GranBio and commercial customers. Back in January, the initial carinata shipment went out as part of the 10-year supply deal with our partner bp, and we intend to expand planted acreage quickly to keep pace with demand coming from the biofuel industry. To sum up, 2023 was a year in which Nufarm posted a highly credible outcome amid difficult conditions while continuing to reach key growth milestones. I'm also glad to report that we stay on course to achieve our financial year '26 revenue aspirations. Moving on to the operating segments now. What the results show across the business is the worth of our diversity both geographically and by segment. As the wider industry's results make clear, the second half proved extremely tough for crop protection. Even so, growth carried on within our North American operations, and we posted yet another very strong result in Europe.
Gregory Hunt
executiveAfter a record outcome in financial years '21 and '22, our APAC business posted a solid full-year result against a difficult industry backdrop. Seed technologies stood out, with robust expansion in our core seeds operation and a larger contribution from our omega-3 and bioenergy growth platforms. Now to each segment. North America turned in a very solid EBITDA figure, powered by strong execution from our team and ongoing backing from our channel customers, even with the market conditions I mentioned earlier. Although sales revenue dropped 14% year-on-year, we held EBIT flat versus the prior year in U.S. dollar terms and successfully navigated a stretch of channel inventory, destocking and price cuts. Deploy and product availability got better across the region after COVID-related supply constraints eased, especially with China reopening in December of 2022. Better product availability and higher interest rates pushed customers toward more just in time purchasing, drawing down channel stocks. Glyphosate sales were slower in particular as customers held off waiting for prices to come down. A better mix and reduced market support softened the hit to EBITDA. We expanded distribution agreements with Sumitomo in Canada and in our T&O segment, locking in our position in key market segments.
Gregory Hunt
executiveWe kept putting money into our supply chain and our manufacturing plants, which keeps us a dependable and effective provider for our channel partners. Coming into the first half of fiscal year '24, channel inventories are at lower levels. And we anticipate supply-and-demand conditions returning to something more typical during the second half of the year. As we said before, we expect margins to stay under pressure through the first half of financial year '24. And lastly, we are making an additional investment at our Chicago Heights site to grow capacity and to achieve better efficiencies. Moving on to Europe, where revenues fell 8%, and EBITDA dropped 6%, versus the prior year in euro terms. That is a strong outcome given what the drought in Spain did to us over the first half and the EUR 25 million hit to revenue caused by product deregistrations. Those effects were partly offset by launches of new products, organic growth and a better gross margin. Earnings remained affected by manufacturing stoppages at our U.K. site, with under-recoveries of EUR 20 million for the period. That site is a globally important operation for Nufarm, where we produce high-margin specialty phenoxy herbicides. Beyond the CapEx program we announced in February of '22 to tackle HSE and reliability problems, we intend a further investment to grow phenoxy capacity at Wyke; and Paul will go into more detail on that in his remarks.
Gregory Hunt
executiveWe anticipate that product deregistrations will have an immaterial effect during the '24 to '26 period. And the renewal of glyphosate in Europe is expected before year-end, with an immaterial impact on Nufarm from a likely phaseout in Germany. For financial year '24, we expect revenue growth, supported by new product introductions and organic growth in key countries. In APAC, EBIT fell 35% year-on-year in Australian dollar terms. While we recognize that some of you may be surprised by how large the decline is, we view this result as vindicating the decisions we made several years ago to restructure this business. Let me explain a little more. Over half of the earnings from this region come from our legacy ANZ business, where we hold strong market share, have a significant investment in manufacturing and retain modest exposure to active ingredient price cycles given the open nature of these economies and our proximity to China. In '23, we navigated a period of significant decline in AI prices. While volumes remained solid, margins were impacted by the decline in prices. Just as we benefited from the increase in AI prices in financial year '21 and '22, we were impacted on the downside in '23, particularly in the second half.
Gregory Hunt
executiveIf you examine EBIT across the cycle, the earnings we're delivering line up with the $50 million to $60 million EBIT target we established at the start of the transformation program for this business, following the 2018, 2019 drought. Good progress continues to be made in diversifying the APAC earnings base so that returns improve. Products newly launched in Australia, along with ongoing growth in our Indonesian business, are strengthening the resilience of earnings. Working capital discipline — especially when it comes to managing inventory holdings of lower-margin foundational products — is contributing to better returns. We're reinvesting in our manufacturing facilities as well. Given that global 2,4-D prices are at a historic low point right now, a modest investment to upgrade our 2,4-D facility here in Victoria will strengthen our competitive position by bringing our manufacturing costs down. We'll temporarily halt 2,4-D acid production during the first half of financial year '24 while this upgrade is completed. Inventory on hand is sufficient to satisfy domestic demand. And although we anticipate first half margins will keep being affected by current global pricing, the upgrade's benefits will come through starting in the second half of the financial year. Further out, we expect margins on foundational products to normalize over the course of financial year '24.
Gregory Hunt
executiveAlso, as we keep broadening what’s in our portfolio—Indonesia and Asia included—that should produce growth in ’25 and ’26. <<inaudible>> seed technologies had an outstanding ’23, with sales up 33% and EBITDA up 67%. That makes 3 years in a row of robust double-digit revenue and earnings gains for the segment. Results for the 2023 financial year <<inaudible>> how strong our base seeds portfolio is, since we increased revenue across every crop, especially hybrid canola. In Australia, the new seed varieties are now planted on every second acre, and we think those varieties will do well in other markets too. Sorghum kept up its strong upward path, with global sales rising 30%, driven by our expansion in South America. Our sunflower business also expanded strongly, as higher sales in markets such as South America more than made up for some declines in Europe caused by the Ukraine conflict. We kept speeding up progress in our high-growth omega-3 and bioenergy platforms. Omega-3 hit several key milestones in the period, among them planting our first hybrids, growing our certified grower base and farm contracting consistent with our oil supply target, and receiving Norway approval for Aquaterra in fish feed formulation. Moving into highly constrained fish oil markets, together with expanded supply and greater downstream market adoption, has put Aquaterra in a very good position for growth into ’24 and beyond.
Gregory Hunt
executiveOur bioenergy platform hit several important milestones as well, and those will help drive expansion and growth in the years ahead. Among them were the first carinata deliveries under the bp contract, the first commercial harvest along with expansion of contract growers in the U.S., and validation during the development phase in both Europe and Australia. Drought conditions that were severe in Argentina cut carinata plantings versus the prior year, yet even with those conditions, new hybrids drew very positive feedback from growers, who needed enough moisture to get crops planted. As we scale and diversify production across our portfolio, we expect weather in any given region to matter less to our performance. Next-generation energy cane hybrids also came to market during the year, and we broadened our customer base. We brought in licensing revenue for the year, and the biggest amount came from our offtake and market development agreement with bp. The biggest was tied to our offtake -- sorry, and market development with bp. Through that agreement, bp makes milestone-related license payments to Nuseed that help underwrite the costs of expanding and developing the Nuseed carinata platform, as we work to scale up production in support of our growth trajectory. In the same way, licensing revenues earned in our energy cane business support scaling up of resources and R&D capabilities.
Gregory Hunt
executiveWith our IP continuing to grow, licensing income should keep showing up in our results going forward. During financial year '23, the seed technologies segment grew its organization by over 75 FTEs, mostly aimed at expanding carinata and omega-3. That organizational growth spanned areas throughout the value chain, such as carbon modeling, sustainability verification, sales, agronomy and downstream marketing. At this point I'll pass things to Paul, who will walk you through the financial details.
Paul Townsend
executiveThanks, Greg, and good morning. Turning now to Slide 13. I'm very pleased with the focused efforts of our team in achieving <<inaudible>> as a result, in challenging industry conditions, underlying EBITDA fell 2% year-over-year. Our underlying gross profit margin rose 170 basis points, driven by the higher relative contribution from seed technologies and an improved sales mix in crop protection. As expected, underlying net financing costs were up 55%, reflecting base rate increases and higher average debt levels through the period. Average net working capital-sales came in at 42%, and I'll cover this in more detail on subsequent pages. We ended the period with net debt of $850 million; and leverage of 1.9x, which sits within our target range of 1.5x to 2x. The balance sheet is strong and we are well funded to pursue our growth objectives. In line with our dividend policy, we declared a $0.05 per share unfranked final dividend, bringing total dividends declared for the year to $0.10 per shares, in line with the financial year '22 dividend. Slide 14. This chart shows our net working capital and cash flow movements. Net working capital was temporarily impacted by abnormally lower payables as we transitioned to a lower inventory position.
Paul Townsend
executiveOperating cash flow reflects seasonally lower earnings in the second half of financial year '23, and the resulting unwinding of net working capital during that same second half of '23, driven by lower receivables balances. As we've said before, operating cash flow correlates strongly with net working capital movements, and this year industry destocking has had an even bigger impact. Inventory came down through the period as expected and is well positioned as we head into the first half of financial year '24. We expect a less-pronounced seasonal build through the first half of '24 than in prior periods. And net working capital should normalize and come down further in the second half of '24 as we move to a steadier cadence of sales and reordering. As a result, we expect strong operating cash flow generation in financial year '24. And overall, looking through the cycle, we anticipate a reduction of net working capital for the full year FY '24. Turning to Slide 15. As the chart on this page shows, the net working capital movement for the year was primarily driven by a reduction in payables as we transitioned to a lower inventory position. We expect payables to normalize as we return to a steadier cadence of sales and reordering.
Paul Townsend
executiveAs we indicated at the halfway point, inventory came down by $324 million in the period, and it stood $138 million below financial year '22. On a year-on-year basis, receivables rose modestly, which mirrors the timing of sales and collections along with the unusually low FY '22 <<inaudible>> position. Average net working-to-sales came in at 42% for financial year '24 -- for financial year '23, and we expect it to return to our target range of 35% to 40% by the close of FY '24, driven by the anticipated net working capital reduction in the second half of financial year '24. Moving to Slide 16. Our CapEx spend is aimed at backing our growth ambitions. Alongside our emphasis on net working capital management, making sure we optimize and rationalize our CapEx spend is a key management priority so we can enable improved returns. Regarding CapEx spend for the full year, there are essentially 3 elements: investment CapEx; intangible spend; and property, plant and equipment. The intangible or product investment covers both a stay-in-business element and growth spend. For crop protection, that includes spend tied to maintaining and defending product registrations, new products and product enhancements. For seed technologies, the spend relates to new hybrids, registrations in new markets and other regulatory investment.
Paul Townsend
executiveThe CapEx for property, plant and equipment covers several safety and environmental programs, along with spending on asset integrity designed to boost the reliability and efficiency of our manufacturing sites overall. That spend also takes in further capacity expansion at Wyke, formulation enhancements and efficiency steps at Chicago Heights, plus 2,4-D efficiency investment in APAC. As we've said before, combined PPE and intangible investment is projected at roughly $200 million a year across the coming 3 years to back Nufarm's growth ambitions — $100 million apiece for intangibles and PPE. We've likewise kicked off a highly significant upgrade to our phenoxy capacity at the Wyke site. The goal of this project is to shift Wyke's capacity toward high-margin products, supporting growth past FY '26. We expect this project to cost circa $140 million across the next 3 years, with most of it falling in FY '25 and '26, and to generate substantial returns comfortably exceeding our cost of capital in FY '26. Consistent with our capital management principles, we evaluate growth opportunities like the Wyke investment through the lens of return on funds employed. And our aim is to set a target return on funds employed that remains above Nufarm's weighted average cost of capital.
Paul Townsend
executiveROFE is down compared with a year ago, mostly because net working capital has been higher than usual, and it ought to get back onto its growth path as EBIT increases and net working capital returns to normal. Moving to Slide 17. The asset-based lending credit facility, along with the 230 -- 2030 USD 350 million unsecured notes, has produced a capital structure that is both flexible and durable and that fits the funding needs of the group's net working capital cycle. Especially this year, the ABL facility has operated efficiently, since the funding is secured against inventory. In addition, the group still retains access to considerable amounts of cash and committed bank liquidity. A working capital unwind that has been slower than usual, owing to industry-wide destocking, has led to September leverage of 1.9x, although that sits within the target leverage range of 1.5x to 2x net debt-to-underlying EBITDA. The seasonal build in net working capital, given the phasing of sales, will probably push leverage above the target range in the first half of '24, but importantly it is estimated to be below or at least within our target range by the end of second half of '24. To summarize: Our balance sheet is strong. We have the capacity and the flexibility to seize opportunities as they arise and to support our growth aspirations. I will now hand over to Rico, who will take you through our crop protection revenue aspirations.
Rico Christensen
executiveThanks, Paul. As Greg said earlier, we keep seeing the payoff from what we've invested in innovative agricultural solutions. Our portfolio backs important sustainability objectives, including zero hunger and life on land. We achieve that by helping our growers get more from less, while offering products that assist them in adapting to climate change and reducing unintended environmental consequence. Innovation and technology will propel Nufarm's sustainable growth. And now we'll update you on our development pipeline, which we initially presented in February 2022, at our Investor Day, and refreshed in May as part of our first half report. We still have a pipeline that will deliver across our core products, our targeted geographies over multiple years; and will strengthen our customer relevance; and support our revenue aspirations. The pipeline is unchanged from our first half report. All of our top projects are active and continue to have an estimated market size of 6.65 billion. That said, over the last 6 months, we've made good progress with our pipeline as projects moved to later-stage gates and eventually are launched and become commercial products. So to help you navigate this slide, we've highlighted <<inaudible>> that has made progress since the first half result 6 months ago.
Rico Christensen
executiveThese accomplishments relate to stage gate progress, entering additional markets, or debuting in the first countries. On the following slide, I'll give a few examples of product launches, but the key takeaway is that we remain on track to reach our 2026 ambition, and the pipeline beyond that also appears promising. As in the first half, we brought a number of products to market during the second half. Keep in mind that our products typically roll out in a staggered fashion, since registration doesn't come through at the same time across all countries, but this stays active until launches have happened in every target market. For instance: we have now secured the first registrations for Joust. That project stays active, as more launches lie ahead. Five platforms make up our portfolio. Foundational solutions like Joust and Carnadine are what we call the bread and milk. Farmers use them each season, and they matter enormously for tackling critical agronomic problems. Within this platform, we've achieved solid progress on several of our key products, including Joust; Optera Pro and Carnadine. Let me add a little more detail on a few of these products.
Rico Christensen
executiveJoust is among the handful of triazole fungicides that are still permitted within the EU, and it stands to gain enormously from other triazole fungicides being phased out. Carnadine is in the same position — it's the sole insecticide left in the neonicotinoid class that's still cleared for sale in the EU, and it will likewise profit from that standing. There was also encouraging news from the EU Commission, which is recommending that glyphosate be re-approved for the next 10 years. As you're aware, we're putting more and more into innovative solutions protected by various forms of IP. I'm happy to report that we've hit a number of significant milestones for those innovative solutions. We obtained the first registrations for our Duplosan family of products in Canada, where they'll be launched later this year as Oxbow and BlackHawk in different mixture combinations. Oxbow controls the herbicide-resistant kochia weed. Kochia is a highly troublesome and difficult-to-kill tumbleweed found across Canada and the U.S. 100% of all kochia weed in Canada is resistant to at least 1 herbicide but sometimes up to 4. We also secured registration of Allstar, a brand-new and unique 4-way mixture combination, including 2,4-D, which acts fast and controls a broad range of weeds.
Rico Christensen
executiveLater this year, this product is set to be introduced in the U.S. turf and ornamental segment also. Terrad'or, previously rolled out with considerable success in Australia, has now been introduced in Indonesia as well. We're also working to expand our Australian registration with additional crops. In Indonesia, we additionally introduced Gracia, a new <<inaudible>> insecticide created by one of our strategic R&D partners. Within biological solutions, we hit key milestones too. Trunemco, our bionematicide, was introduced in the U.S. last year. And earlier this year, we brought the product to Brazil alongside our distribution partners. Trunemco is a biological nematicide that targets nematodes — soil parasites that live off crops such as soybean and corn, hurting yields. Biological nematicides offer a way to control nematodes, and that category is now the fastest-growing one inside the broader biological market. We recently secured registration for Trunemco in China and intend to launch later this year. Over the past few months, we've also filed our registration for Exsolant and Simpell in the U.S. Spinosad, the most important bioinsecticide worldwide today, is contained in these products. With this submission, we're positioned to launch near the end of '24 or at the start of 2025.
Rico Christensen
executiveIn India, we recently introduced our Cuproxat fungicide, and we anticipate growth in this key market. India already ranks as the <<inaudible>> largest biological market, and we're glad to now have a presence there with a core product. On the adjacent solutions front, we brought out Prospr together with one of our partners. Prospr is an autonomous self-propelled sprayer, and this is genuinely a first for our Croplands business. The knowledge about new application technologies that our Croplands business is giving us is extremely valuable and gives us a distinctive competitive advantage in innovation that no peer of ours in the crop protection industry possesses. With crop.zone, we also see solid progress over these last 6 months, both on the technology side and with new commercial partners in Germany. Similarly, we drew the interest of 40 key customers at a NUCROP field day in Spain, where we showcased the technological advances of the crop.zone technology combined with our Volt.fuel product. In the integrated solutions space, I'm happy to tell you that the U.S. EPA has agreed to recognize carinata as a crop for label extensions. That means in our crop protection business we're able to add the carinata crop to our product labels and back our Nuseed colleagues with high-quality agronomic solutions.
Rico Christensen
executiveOver in Serbia, we ran a joint field day for Nufarm and Nuseed as well, hosting 200 customers who came from across Europe, Africa and Middle East, and we put the combined seed and crop protection solutions of Nufarm on display. Customers responded overwhelmingly positively. Those are only a few examples. As a matter of fact, the second half brought more product launches, and I would also like to point out that, broadly speaking, these new products carry higher margins, and because of that they contributed to the full-year improvement in average gross margin. On the whole, we feel quite good about how the second half went. And as I said earlier, our pipeline remains on track to deliver our 2026 aspiration. I will now pass things to Brent, who will speak to some further very exciting growth opportunities.
Gregory Hunt
executiveBrent, was that you? I couldn't quite catch it.
Brent Zacharias
executiveYes. Are you able to hear me?
Gregory Hunt
executiveYeah. I can't make out what you said.
Brent Zacharias
executiveAll right, here we are. Appreciate it, Rico. Morning, everybody. Since Greg has already walked you through the main highlights of this year's results, I'll spend my time on growth and the outlook. I've laid out before what we're aiming for in the seeds technologies business across the medium to long term. Today I'm glad to report that the internal targets underpinning those aspirations are well on track. What gives us confidence in sustained strong growth is the accelerating pace of technology and market adoption, both at the farm gate and among our downstream customers. Bringing innovative, sustainable plant-based solutions to new markets remains a highly strategic, profitable and transformational position for our proprietary seed technologies platform. Going forward, seed technologies should stay in a high-revenue growth phase, backed by ongoing investment across our platforms. Having successfully grown the contracted production supply base for omega-3 canola in the last growing season, we're now building downstream customer sales and deliveries of Aquaterra and Nutriterra. In FY '24, we intend to expand omega-3 contract plantings further, supporting our goal of doubling oil production and supply to take advantage of greater market adoption into the FY '25 period.
Brent Zacharias
executiveWe're also looking to grow carinata plantings substantially, with a solid upward path and wider geographic spread — that includes more expansion across Argentina, Uruguay and the U.S.A., plus our first commercial plantings in Europe and Brazil, while continuing to push developments forward in Australia. Energy cane, the newest piece of our bioenergy platform, is transitioning out of development and into its expansion phase, and stronger product development and commercial capabilities are backing the recent launch of next-generation hybrid <<inaudible>>, which shows over 30% more sugar and ethanol output per hectare compared with existing standard sugarcane products on marginal and degraded land. As additional scale-up investments in the energy cane business carry on, we anticipate a more material contribution after the FY '24 and FY '26 periods. Revenue growth in FY '24 should come mainly from omega-3 and bioenergy. Seeds, crop revenues are likewise projected to be higher, though not to the degree of the record growth delivered in FY '23. Because of the timing of the relevant milestones, licensing income anticipated for FY '24 should be below FY '23, but it will keep providing meaningful support for additional investments in scale-up and expansion activity. FY '24 EBITDA should rise, though more modestly than in FY '23, ahead of an expected acceleration in EBITDA growth over the years that follow.
Brent Zacharias
executiveIn summary, FY '23 was a really robust year. Taken together, the results we delivered financially, the strategic progress made, and the growth we see ahead all signal that we are solidly on course to hit a revenue goal of $600 million to $700 million by FY '26, with EBITDA margins of 20% to 25%. I'll turn it back over to Greg now. <<inaudible>> it wasn't tied directly to the '23 result, it does highlight why we feel confident that we're on track to reach our '26 revenue aspirations. From a macro standpoint, the forces driving our business are still quite favorable. Worldwide food demand is poised to climb substantially as the global population grows. And at the same time, pressure is mounting to satisfy our food requirements in a more sustainable way. Progress in science and technology is transforming how we use land and plants to provide not only food but also energy and a broad array of other new products. Nufarm sits at the leading edge of these shifts, and much of that comes down to our emphasis on innovation and technology. We expect demand for our products to keep expanding and to propel our revenue and earnings. Our balance sheet is strong enough to support this growth and to seize opportunities as they come up.
Brent Zacharias
executiveNow looking at what's right ahead of us. Supplies relative to usage for grain and oilseed are still tight. Prices for grain are still appealing, which is propping up what growers plant and their appetite for crop protection products. In seed technologies, we're budgeting for additional EBITDA expansion in '24, though at a slower pace than what we saw in '23, since we keep putting money into expanding our omega-3 and bioenergy platforms. Taken together, omega-3 and carinata should account for a substantially larger share of seeds revenues starting in '24. We're anticipating sustained momentum behind crop protection product introductions in '24, picking up speed across '25 and afterward, as Rico laid out. And our product pipeline is robust enough to back our '26 objectives. Our balance sheet is strong. And by the close of financial year '24, we anticipate staying comfortably inside or under our net leverage target range of 1.5x to 2x EBITDA. Over the first half, we expect trading conditions to stay difficult while the industry absorbs a reduced level of input costs, with a return to growth coming in the latter half of fiscal '24. Crucially, as we've noted repeatedly, we're still on course to hit our '26 revenue goal of $4.6 billion. With that, Rachel, I'll turn things back over to you.
Brent Zacharias
executiveAnd now we can open things up for some questions.
Operator
operator<<operator_script>> Our initial question is from Evan Karatzas at UBS.
Evan Karatzas
analystStarting with just the first one for me — could you describe what the inventory picture looks like right now, both for your own company and across the industry; and then, I suppose, how that ties into the potential balance sheet deleveraging you're anticipating or referring to as well, please?
Gregory Hunt
executiveYes. Thanks for that question, Evan. As we've mentioned, channel inventories — and you'll have picked this up from a lot of commentary from our peers — are fairly low across most regions. It's at the manufacturer level that inventories are elevated. If you look at our inventories, roughly 50% are herbicides, where stock turns tend to be higher. And we expect that inventory to move as we get closer to the Australian winter and the North American hemisphere spring crop in Q2 and Q3. And while it's really sort of too early to talk about the earnings outlook — so we're not giving guidance. However, I can probably offer some high-level commentary on current trading, the demand outlook and therefore inventory levels that may help answer that question. In APAC, we are planning for an improved result as we work through the remaining inventories, which sit at relatively low levels. And I wouldn't expect the same price impact that we saw in Q4 of '23. In North America, we've got higher absolute inventories. And I would expect higher revenues in '24 but continued margin pressure as we sell down. And in Europe, I guess probably an improved result because of less impact of regulatory outs.
Gregory Hunt
executiveWe do still anticipate better manufacturing performance, though not at the level we intend to reach in a couple of years given the capital we are putting into that plant. And as Brent already laid out, we are projecting $50 million to $70 million in omega-3 revenues in '24, then doubling out to '25 and continuing to grow beyond that. Paul, would you like to offer some particular remarks regarding inventory and leverage?
Paul Townsend
executiveYes. So Evan, as we've kind of indicated, I would anticipate inventory coming down even more. Right now we're sitting at roughly 155 days, and our typical inventory level—depending on the products and so on—averages somewhere in the range of 120 to 140 days, varying by product. So if you look at that, there's likely, shall we say, another couple hundred million that could be taken out of that figure fairly easily. The question is when, not whether, as Greg mentioned, so my expectation is that it won't truly normalize until we get into the second half of '24, once we've sort of worked through the normal. Like I said in my remarks, again, we'd reach normal reordering and sales program in terms of when the cadence gets back to normal. Another factor to keep in mind is how our payables sort of follow along with that. And really it's the difference between your payables and your inventory that—and clearly it's your variable net working capital tied to that, so if we can trim that back—when I say trim it back, what I mean is that as we reorder, our payables rise.
Paul Townsend
executiveSo because of that, the gap between safe and what it is kind of shrinks right now. That means it might land anywhere from 200 to 400, based on — that is, the difference between those two — based on how much inventory comes down. So in my view, actually this is all — I'll put this quite plainly, having said it to plenty of people across plenty of meetings — this will be a second-half story, meaning judge us on the back half of '24 and how that turns out, since there's still work left before we're back to a normal position.
Evan Karatzas
analystAlright, thanks a lot for that. If I could just fit in one more — perhaps for Brent — I'd like to know what you're picking up on the ground, whether from customers or across the industry, specifically regarding your omega-3 product as well, please.
Brent Zacharias
executiveYeah, absolutely. Thanks, Evan. I'd say we're definitely at a point in the market now. And I think it's clear to everyone that fish oil supply has faced fundamental challenges over this past year, with the first Peru quota being cancelled. And we're seeing record-high fish oil prices simply because of the constraints in that marketplace. That, combined with several years now of customer experience with Aquaterra, means we're seeing very strong demand and really strong signals for market adoption, which is great given that we've been expanding our supply base. So I think we're in a short- to medium-term dynamic here where we can see very strong market adoption both on Aquaterra -- and then also, as we've outlined today, seeing good adoption and more strategic relationships on the Nutriterra human health side. So I think we're at a place in the market where they really need us, and it's a good place to be right now.
Operator
operatorOur following question is from Richard Johnson at Jefferies.
Richard Johnson
analystI just want to add a couple of specifics. Greg, on your seeds guidance — the slide mentions modest growth. Did you intend that to mean growth that's more modest?
Paul Townsend
executiveYeah, I'll take that one. So, the way I'd frame it is that this represents a year-over-year increase. What you should keep in mind is that we anticipate licensing income declining, along with the EBITDA tied to it, but expansion in omega-3 and carinata should essentially offset any gap left by the licensing revenue and EBITDA that falls away. So it is growth, though a modest amount of growth relative to the fiscal year — as we close out the fiscal year...
Gregory Hunt
executiveSomething we couldn't quite make out there — 67%.
Paul Townsend
executiveYes, 67%.
Richard Johnson
analystYes, alright, that's great. And could you help us get a feel for how you see the first-half versus second-half breakdown shaping up in '24...
Gregory Hunt
executiveYeah, yeah, yeah, no. When we reported at the half, I believe we indicated that '23 would probably come in around 70-30. We actually ended up at 72-28, and for '24, my expectation is that the '24 split will be closer to 60-40.
Richard Johnson
analystThanks. Now just a couple of questions on seeds, probably for Brent. Brent, when you look at the '26 aspirational target and the ranges you've provided for both revenue and margin, and then consider the tone of the commentary you're giving right now, particularly around omega-3 — what explains the difference in that range? Or to put it another way, what has to happen for you to reach the high end of that range?
Brent Zacharias
executiveAbsolutely, Richard — thanks. I think we've reached a point where 2025 and 2026 are genuinely just around the corner for us, and the fact that we're laying out $50 million to $70 million in revenue from omega-3 in FY '24, coming from FY '23 plantings, speaks to that. We're also indicating that our directional aim is to double that when it comes to planting for FY '24, which ought to double that revenue into 2025. And if you trace that kind of trajectory, along with the other growth factors we identify in the business, then I think — provided market conditions stay favorable and we meet our grower expansion targets — we can say that range is one we feel very comfortable with right now and, hopefully, we're on a path to landing in it either sooner or nearer the top end.
Richard Johnson
analystThat is quite useful. And then, along similar lines, would you remind me how the trajectory for carinata plantings appears across the coming few years, just in terms of growth — in a growth sense?
Brent Zacharias
executiveAbsolutely, I’m glad to offer some perspective on how to approach that. As Greg and I described, we fell short of our planting goals this year due to the severe drought in Argentina. Still, the growers who did plant were quite happy—especially where moisture was available—because we had just introduced our new hybrids. So we’d say we expect to get back on track in Argentina for that growth in '24, and on top of that, we now have our second year of expansion in the U.S., our second year in Uruguay, and our first year in Brazil and in Europe. When thinking about entering new markets, our usual approach is to plan for roughly 5,000 hectares and then target doubling that annually after that. Hopefully, that gives you a bit of a trajectory to consider. We see ourselves not only expanding geographically but also being in a position to accelerate quickly with our hybrids that suit each of those markets.
Operator
operatorWilliam Park from Citi has our next question.
William Park
analystWhile we're still on the topic of seed technologies, may I ask about the EBITDA margin target range for FY '26? I mean, if my math is right, since you've already reached the top end, so to speak, would it be fair to say there's some upside to that margin target? Or do you expect ramp-up costs and timing tied to carinata and omega-3 to hold margins around that level until there's meaningful improvement beyond FY '26?
Paul Townsend
executiveDo you mind — I’ll just jump in on that — what’s really lifting the margin is essentially the licensing income, which is a lumpy outcome, so to speak, in the FY '23 period. So that is pushing up, if you will, the EBITDA margin beyond what we otherwise would have anticipated. So it will fall away next year owing to that lumpiness, so to speak, and as a result, we — it isn’t that there’s upside. It’s simply that this year is somewhat unusual thanks to these licensing fees that are pushing the EBITDA margin higher than what we would have — under other circumstances we had been planning for.
William Park
analystAnd if I may push a little further on this. What are you anticipating for margins relative to FY '21 levels as well? I mean, in '24, are you at roughly FY '21, FY '22 levels? Or do you expect some improvement over FY '22 levels? I just wanted to get a sense of how you're thinking about this.
Gregory Hunt
executiveBrent, would you like to speak about how growth is tracking?
Brent Zacharias
executiveYes, absolutely. To expand on that answer a bit more: part of what factors in here is the mix of products and the margins within every one of our product lines — not only omega-3 and carinata. We've observed margin expansion throughout the entire business across each of the crops, and also across each of the new technology platforms, so I'd say we will comfortably land inside that 20% to 25% EBITDA margin range, but we've kept enhancing the quality of the business right across the whole seed technology platform, so yes. I think you could — certainly as Paul has outlined, holding at the 25% EBITDA margin level might prove difficult next year, but we're continuing to improve the quality of the business. And I think certainly — being at the baseline of where we stood in '22 and above is clearly in sight.
Operator
operatorJohn Purtell from Macquarie has the next question for you.
John Purtell
analystI only had a few questions. Regarding what you're observing when it comes to AI prices and a few of the key trends in that area — I believe there's a chart in the appendix — but clearly, if there's a perception that prices have hit a floor or are reaching one, that ought to support reordering.
Gregory Hunt
executiveJohn, it's Greg here. Look, I figured — at the halfway point, if you check what I said in my commentary, I figured we'd kind of hit the floor there, but obviously, if you look at those charts, I mean, both glyphosate and 2,4-D dropped even more in the second half. But we — definitely now, as we head into October and November, we're beginning to see glyphosate prices climbing, and — and certainly 2,4-D too. So, as we frequently put it, nobody rings a bell at the bottom, but every indication suggests we'll see active ingredient prices begin to rise. Still, I wouldn't anticipate any meaningful movement, honestly, until this inventory gets worked through in the first half and we return to more typical demand-supply dynamics in the second half of '24.
John Purtell
analystOnly the latter has some connection to that. I see what you're saying—the North America reordering is anticipated in Q3 rather than Q2. Would you call that more of a typical seasonal trend, so to speak? And presumably it's likewise affecting the SKU you mentioned before.
Gregory Hunt
executiveYes. I believe I mentioned Q2 and Q3, as spring cropping begins across the northern hemisphere — though, as I noted, our inventory levels are proportionately higher in North America. So I'd anticipate revenues rising over '24, but with margin pressure continuing to some degree, partly offsetting the contribution that higher revenues bring.
John Purtell
analystAnd one last thing on that. Greg, you said earlier regarding APAC that you expect a better outcome once those pricing effects have worked their way through, especially in the second half — but what seasonal conditions are you factoring in there?
Gregory Hunt
executiveI mean, we generally plan for what you'd call an ordinary season. Given that El Niño is forming, it seems fair to think we might end up with a reduced winter crop — but honestly, it's far too soon to make that call. We're being a bit more careful about how much raw material we import for the winter crop, though if you review past El Niño occurrences across many years, El Niño doesn't automatically mean drought — definitely not the kind of thing we experienced in 2019 and 2020. Still, every signal points to a smaller crop, a smaller winter — and for sure a smaller summer crop, which doesn't really matter much to us in any case; plus a reduced winter crop in '24. So I'd put it this way: we're taking a careful stance on how we're stocking up going into '24, if that answers your question.
Operator
operator<<operator_script>> The following question is from Jonathan Snape at Bell Potter.
Jonathan Snape
analystIs my voice coming through clearly?
Gregory Hunt
executiveAbsolutely, Jonathan — thank you.
Jonathan Snape
analystPerhaps Paul should take the first one. I saw you had some remarks about working capital, especially payables. If I look at your off-balance-sheet facilities — and I realize you don't want these questions, but it's sort of dropped down — roughly 4% of your payables is financed off balance sheet this year, while historically, I think over the last 5 years, it's been closer to 1/4 of your payables financed by those facilities. And it appeared that almost 300 million of debt came onto the balance sheet from off balance sheet. As you look toward next year, when you begin that reordering process on actives and you shift from finished to active ingredients and inventory balanced, should I expect that to normalize back to roughly what we saw over the last 5 years?
Paul Townsend
executiveYes, to start with, Jonathan, I really enjoy the questions you send in. That's fine...
Gregory Hunt
executive<<inaudible>>.
Paul Townsend
executiveYes, absolutely. The quick response is affirmative, since these payables are stale — meaning they're aged payables. That's the reason we reached into our own pockets. We mentioned at the half-year point that our hands were in our pockets until we had more or less worked our way through the inventory. So once we return to a typical reordering rhythm, we do anticipate drawing on the supplier financing facility. We use it for a solid reason, given that it gives us 180-day terms. As a result, it will extend our payables days in line with that. So yes, we will draw on that facility, and you'll observe a shift from essentially on balance sheet to off balance sheet.
Jonathan Snape
analystOkay, great. And look, can I just ask about the licensing revenues? And I want to make sure I’m looking at the right segment note here. I think it was around 19 million last year. It was 55 million this year. Is all of that carinata revenue coming through? Is there something else included there? And then the follow-on would be where should I be thinking, next year, that number kind of heads back to.
Paul Townsend
executiveYes, so to put it briefly, the answer is yes. That difference is essentially the BP license fees, so the way you should view it for next year is that this gap gets cut in half.
Jonathan Snape
analystRight, so that's a pretty significant headwind — roughly $22 million.
Paul Townsend
executiveLook, that's revenue, and as you know, in an EBITDA context — remember, this is funding the expansion and the carinata-related activities — so it isn't one for one. So you really have to think about it this way: well, that's revenue, but the EBITDA impact is...
Gregory Hunt
executiveLess.
Paul Townsend
executiveFewer, indeed — that’s right.
Jonathan Snape
analystAll right, all right. And well, this might be one for Brent, regarding the omega-3 side. I believe you mentioned that doubling volume would double revenues, but if I recall correctly, what you've priced is currently far off market on pricing. Like the algae guys are above $8,000 a tonne. And you were, what, below $3,000, so if we're considering a more realistic picture in '25, '26, if -- where oil prices stand, I mean, how much ability do you have to begin adjusting the pricing mechanism on that omega-3 product? Because it really seems you guys are significantly under where fish oil, fish meal, algae oil sit right now. I'm just trying to work out how long you've got that stuff running for, how much ability you have to adjust it.
Brent Zacharias
executiveOkay, a few thoughts on that. We provided a revenue range, and one reason is that depending on when crushing happens and when logistics line up, it's possible not all volumes produced in FY '23 get sold within the '24 financial year. A portion could spill just slightly into calendar year '24 — that's why there's a range. On your pricing question: we're currently in many conversations with our long-term industry partners about what the right kinds of pricing mechanisms and structures should look like, given that the market has changed fundamentally over these last 6 to 12 months. So what I'd say — probably repeating my earlier remarks — is that the industry truly needs a scalable, sustainable solution of this kind at this moment. So I'd say there's, I think, a really solid balance between us and the industry as we work to make sure we can offer them pricing solutions that are competitive while also reflecting the new market dynamic. So I realize that isn't very specific for you, Jon, but I'd hope both of those 2 points help you conclude that we are definitely seeing upside in the current market.
Brent Zacharias
executiveWe also believe that when other fishing quotas recover, fish oil pricing will likely correct. But fundamentally—and many market analysts agree—there's going to be a fundamental lift relative to what was once the 5-year average pricing in these markets. Going forward, it's probably higher now.
Jonathan Snape
analystYeah, but look — if Corbion is able to achieve 30% growth in volume plus 20% on pricing with an algae product, then I mean, why wouldn't Nufarm be able to secure double-digit pricing on double-digit volume when the two of you are essentially going head-to-head on that same product?
Brent Zacharias
executiveYeah, so — and honestly, I wouldn't rule that out at all, Jon, that's really the point I'm getting at, so we're definitely in a strong position to know how to handle ourselves in that market. It's just that we're probably being pretty cautious with the guidance we're giving for the near term as well.
Jonathan Snape
analystOkay, and then one final question. Greg, this one may be for you. Regarding APAC, did I hear that right? Earlier you mentioned that Australia now accounts for, I believe, 50% of EBIT, which would suggest it's currently generating roughly $35 million or so. And your view is that it can return to that $50 million to $60 million range. Would that follow a second-half trajectory, or is it more likely to materialize in '25, assuming a normal season?
Gregory Hunt
executiveI think what I — yes, absolutely. What I was attempting to convey was that — just give me a second. I'd check my notes here. For the legacy Australia and New Zealand business, our target through the cycles was $50 million to $60 million in EBIT. And looking at financial year '23, the figure was actually $42 million. And when you look at what Australia and New Zealand contributed from FY '20 to FY '23, the average came to $54 million. So my point is that while the '23 result may appear weak next to '21 and '22 — however, if you view it through the cycles, given that '21 and '22 were genuinely outperformance years, then what I'm getting at is that we — that business is delivering to where we believe we could get it to. And I'll add one other point: return on assets has improved significantly across that same period.
Brent Zacharias
executiveJon, may I tack on one further point regarding Paul’s answer to your question about licensing revenue? I’d like to clarify that this isn’t solely bp licensing income. As I believe Greg also noted in his script, we receive licensing income from several parties, so although they are the largest — they are the most significant — it isn’t only bp license income. I simply wanted to ensure that point is clear.
Operator
operatorThat brings us to the end of the question-and-answer session. At this point, I'll return the call to Mr. Hunt, who will offer some closing comments.
Gregory Hunt
executiveThanks, Rachel. And listen, I appreciate everyone taking the time to join. Perhaps I could just highlight a handful of main takeaways by way of recap. Crop prices are still fairly appealing, which means demand from growers stays robust for our seeds as well as our crop protection offerings. We anticipate better trading in the back half of the year as we work through those inventory levels we discussed during the first half. Our crop protection pipeline is healthy, and with active ingredient costs on the rise, that gives us some tailwinds. We've also established the platform for ongoing growth from our seed technology platforms. Our leverage goal is still to sit comfortably inside 1.5x to 2x by the close of financial year '24, and just as importantly, we're still on track to meet our financial year '26 aspirations. I'm looking forward to connecting with some of you in the coming days. Thanks, Rachel.
Operator
operatorThat brings today's conference to a close. We appreciate everyone for joining in. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.